Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Sure: Long-Term Follow-Up of Bepirovirsen in Chronic Hepatitis B
NCT04954859Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2021
- Primary completion
- Jan 2029
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 29
01
Overview
A Phase 2 trial of bepirovirsen in hepatitis B (HBV), sponsored by GSK. Started Dec 2021; status: active, not recruiting.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04954859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954859.